Patents Assigned to SUMITOMO PHARMA CO., LTD.
-
Patent number: 11752069Abstract: A cellular medicine transfer system includes: an adapter for a cellular medicine container including a first flow channel and a second flow channel through each of which a liquid and cells can flow; a cellular medicine container to which the adapter is attached, and in which a cellular medicine to be transferred is stored; an administration medium storage container that communicates with the first flow channel, and in which an administration medium is stored; a collection container for collecting a cellular medicine, that communicates with the second flow channel of the adapter; and a powering device that imparts motive power for transferring the administration medium from the administration medium storage container through the first flow channel to the cellular medicine container, and for transferring the cellular medicine and the administration medium from the cellular medicine container through the second flow channel to the collection container.Type: GrantFiled: November 27, 2018Date of Patent: September 12, 2023Assignees: HEALIOS K. K., SUMITOMO PHARMA CO., LTD.Inventors: Masakazu Inamori, Dai Otagiri
-
Publication number: 20230281391Abstract: A computer-implemented method, comprising the steps of receiving a plurality of texts, each of the plurality of texts comprising a plurality of syntactic units; extracting, for each of the plurality of syntactic units, at least one subject and/or at least one object; classifying, for each of the plurality of syntactic units, whether each of the plurality of syntactic units comprises a relation; extracting, for each of the plurality of syntactic units, based on the at least one subject, the at least one object, and the syntactic unit, a predicate; normalizing, for each of the plurality of syntactic units, the at least one subject and the at least one object, and appending identifiers to the at least one subject and the at least one object, respectively; and outputting, for each of the syntactic units, a triplet comprising the at least one subject, the at least one object, and the predicate.Type: ApplicationFiled: March 6, 2023Publication date: September 7, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Yoann Mamy Randriamihaja, Mingzhe Tao, Mourad Sarrouti
-
Publication number: 20230265061Abstract: The present invention relates to a compound of formula (1) wherein Q1 is halogen atom, Q2 is hydrogen atom, etc., X, Y, and Z are nitrogen atom or oxygen atom, and R1 has a given structure, or a pharmaceutically acceptable salt thereof, and a medicament comprising the compound for treating and/or preventing a disease such as epilepsy.Type: ApplicationFiled: March 16, 2021Publication date: August 24, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Yoshiaki ISOBE, Tomoyuki TANAKA, Hirotaka MIYACHI
-
Patent number: 11731960Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.Type: GrantFiled: July 22, 2022Date of Patent: August 22, 2023Assignee: SUMITOMO PHARMA CO., LTD.Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
-
Patent number: 11718592Abstract: The present invention relates to a compound of formula (1) wherein Q1 is halogen atom, Q2 is hydrogen atom, etc., X, Y, and Z are nitrogen atom or oxygen atom, and R1 has a given structure, or a pharmaceutically acceptable salt thereof, and a medicament comprising the compound for treating and/or preventing a disease such as epilepsy.Type: GrantFiled: September 16, 2022Date of Patent: August 8, 2023Assignee: Sumitomo Pharma Co., Ltd.Inventors: Yoshiaki Isobe, Tomoyuki Tanaka, Hirotaka Miyachi
-
Publication number: 20230240994Abstract: A particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%, and a process for preparation of the hollow particle, which includes granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.Type: ApplicationFiled: April 5, 2023Publication date: August 3, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Mitsuaki KOBIKI, Yasushi OCHIAI
-
Publication number: 20230240999Abstract: Provided is a manufacturing method of particles coated with coatable microparticles. The method is a manufacturing method of particles coated with coatable microparticles, comprising the step of adding the coatable microparticles to an inner core comprising a component of interest and a macromolecule, and, while rolling the mixture, coating the mixture while spraying a solvent that can dissolve the macromolecule, wherein the particles coated with the coatable microparticles are coated, component of interest-containing hollow particles.Type: ApplicationFiled: April 11, 2023Publication date: August 3, 2023Applicant: SUMITOMO PHARMA CO., LTD.Inventors: Takumi ASADA, Mitsuaki KOBIKI
-
Patent number: 11702431Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.Type: GrantFiled: April 26, 2019Date of Patent: July 18, 2023Assignees: Sumitomo Pharma Co., Ltd., THE KITASATO INSTITUTEInventors: Toshio Kanai, Sachiko Koike, Takayuki Fukaya, Shunichiro Uesugi, Shingo Mizushima, Hitoshi Suda, Yuki Mizukami, Yohei Ikuma, Toshiaki Sunazuka, Yoshihiko Noguchi
-
Publication number: 20230219970Abstract: The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.Type: ApplicationFiled: March 21, 2023Publication date: July 13, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Hitoshi BAN, Seiji KAMIOKA, Yusuke SAWAYAMA, Miki HASHIZUME
-
Patent number: 11696895Abstract: Provided is a manufacturing method of particles coated with coatable microparticles. The method is a manufacturing method of particles coated with coatable microparticles, comprising the step of adding the coatable microparticles to an inner core comprising a component of interest and a macromolecule, and, while rolling the mixture, coating the mixture while spraying a solvent that can dissolve the macromolecule, wherein the particles coated with the coatable microparticles are coated, component of interest-containing hollow particles.Type: GrantFiled: October 18, 2018Date of Patent: July 11, 2023Assignee: Sumitomo Pharma Co., Ltd.Inventors: Takumi Asada, Mitsuaki Kobiki
-
Publication number: 20230210850Abstract: A process for preparing a compound of Formula (1a): or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 13, 2023Publication date: July 6, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Yohei IKUMA, Kengo TOJO, Ryo FUKAZAWA, Shuji MASUMOTO
-
Publication number: 20230202991Abstract: The present invention relates to a medicament for treating various nervous system diseases or psychiatric diseases, comprising a compound of formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient, wherein R1 is hydrogen, etc., R2 is halogen, etc., R3, R4, R5, and R6 are hydrogen, etc.Type: ApplicationFiled: July 6, 2021Publication date: June 29, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Tomoyuki TANAKA, Yoshiaki ISOBE, Hiroyuki KITANO, Hiroaki TANAKA, Shun NARAI
-
Patent number: 11684698Abstract: A sphere-like cell aggregate according to one embodiment of the present invention comprises: a core part containing neural retina; and a covering part continuously or discontinuously covering at least a portion of a surface of the core part.Type: GrantFiled: September 7, 2018Date of Patent: June 27, 2023Assignees: Riken, Sumitomo Pharma Co., Ltd.Inventors: Masayo Takahashi, Michiko Mandai, Suguru Yamasaki
-
Publication number: 20230183316Abstract: The present disclosure includes a pharmaceutical composition for treating a cancer in an HLA-A*02:07, HLA-A*03:01, HLA-B*15:01, or HLA-B*27:05-positive subject comprising a WT1-derived cancer antigen peptide or a peptide conjugate containing the peptide.Type: ApplicationFiled: May 11, 2021Publication date: June 15, 2023Applicants: SUMITOMO PHARMA CO., LTD., INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.Inventors: Masashi GOTO, Natsuko SUGINOBE, Megumi NAKAMURA
-
Publication number: 20230172527Abstract: There are provided a system, an apparatus, a program, and a method for enabling objective evaluation of a three-dimensional cognitive ability through quantification. A three-dimensional cognitive ability of a measurement target person is evaluated by acquiring a position of a moving object, the position enabling identification of a distance between the moving object and the measurement target person, by receiving input of an active response of the measurement target person taken in response to a three-dimensional position of the object recognized by the measurement target person, and by determining whether the position of the object that is acquired and the response that is input correctly match.Type: ApplicationFiled: May 7, 2021Publication date: June 8, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Yasushi OCHIAI, Kazuki KASAI
-
Publication number: 20230170075Abstract: Systems and methods for implementing an exposure progression that improves an ability of a subject to manage a psychiatric or mental condition of the subject are provided. An exposure progression includes a plurality of categories in a hierarchical order. Each category is associated with one or more experiences, and each experience is associated with a digital reality scene that manifests a challenge. In some embodiments, the hierarchical order is generated or modified dynamically based at least in part on the level of success that a subject has had in one or more challenges, producing an exposure progression that it not only tailored to each subject but also with personalized timing and/or nature of the exposure practice.Type: ApplicationFiled: December 1, 2022Publication date: June 1, 2023Applicants: BehaVR, Inc., Sumitomo Pharma Co., Ltd.Inventors: Aprilia Alam, Brandon Hedges, Christina Zaluski, Eleanor Anderson, Georgia Mitsi, Joyce Tsai, Morgan Taylor, Risa Weisberg, Sarah Zadd, Todd Grinnell
-
Patent number: 11661397Abstract: The present invention provides a 1,4-disubstituted imidazole derivative of formula (1?) wherein ring Q1 is optionally-substituted C6-10 aryl group, etc.; R1 and R2 are independently hydrogen atom, etc.; W1 is optionally-substituted C1-4 alkylene group; W2 is —NR3aC(O)— wherein R3a is hydrogen atom or C1-6 alkyl group, etc.; ring Q2 is 5- to 10-membered heteroaryl group, etc.; W3 is optionally-substituted C1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R4 is independently halogen atom, optionally-substituted C1-6 alkyl group, etc.; R5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.Type: GrantFiled: October 16, 2020Date of Patent: May 30, 2023Assignee: Sumitomo Pharma Co., Ltd.Inventors: Hitoshi Ban, Manabu Kusagi, Shingo Tojo, Futoshi Hasegawa, Miki Hashizume
-
Publication number: 20230149357Abstract: The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson’s disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson’s disease and/or an effect of preventing the recurrence of the same.Type: ApplicationFiled: December 28, 2022Publication date: May 18, 2023Applicant: Sumitomo Pharma Co., Ltd.Inventors: Taro KATO, Satoko SHIMIZU
-
Patent number: 11649432Abstract: The present invention provides a method for more efficiently producing retinal pigment epithelial cells from pluripotent stem cells. The method of the present invention for producing retinal pigment epithelial cells includes the following steps: (1) a first step for culturing a pluripotent stem cell in a medium comprising an FGF receptor inhibitor and/or an MEK inhibitor for a period of not more than 30 days, and (2) a second step for culturing the cell obtained in the first step in the presence of a Nodal signal transduction pathway inhibitor and/or a Wnt signal transduction pathway inhibitor to form a retinal pigment epithelial cell.Type: GrantFiled: September 8, 2016Date of Patent: May 16, 2023Assignees: SUMITOMO PHARMA CO., LTD., HEALIOS K.K.Inventors: Satoshi Ando, Takao Kuroda
-
Patent number: 11639357Abstract: The present invention relates to the compound of formula (I) wherein R1A, R1B, R1C, and R1D are hydrogen atom, etc., R2A and R2B are hydrogen atom, etc., R3A, R3B, R3C, and R3D are hydrogen atom, etc., L is bond, etc., V is C1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents.Type: GrantFiled: July 31, 2020Date of Patent: May 2, 2023Assignee: Sumitomo Pharma Co., Ltd.Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Miki Hashizume